MaaT Pharma

MaaT Pharma (Microbiota as Therapy) is a French biotechnology company founded at the end of 2014. It aims to treat serious diseases associated with gut microbiome imbalance. The company has developed the first treatment regimen based on autologous microbiota therapy. MaaT Pharma envisions its first therapeutic application for patients with leukemia and bone joint infections, where its primary treatment addresses dysbiosis. MaaT Pharma was co-founded by a team that brings together world-class medical science and business expertise, committed to becoming a leader in microbiome preservation and the treatment of dysbiosis.